News • Rapid antigen testing at point of care

AI-assisted SARS-CoV-2 testing: Cooperation for first live project in Munich

Medicus AI announces the successful launch of its first live project under SafePlay, the digital platform supporting rapid antigen testing, which went live in partnership with Roche Diagnostics Germany and 21Dx in Munich this month.

Image source: Roche

Medicus provides operators with a tech-enabled end-to-end solution that supports the logistical aspects of testing, managing the administrative workflow from registration to results delivery. This is the first deployment of the Safeplay solution, which is powered by the Medicus AI platform. The Vienna-based health tech company continues to support diagnostic labs and healthcare providers in their daily challenges including emerging ones such as Covid-19.

After successfully implementing the solution at our testing center in Munich, we have quickly decided to roll out the solution to all our antigen testing teams (mobile and fix centers) in Germany

Beatus Buchzik

“In recent weeks, many countries have adopted rapid antigen testing as part of their national testing strategy to support critical infrastructure like elderly homes, hospitals or even set up testing stations for the general public,” says Rafael Vartian, Head of Business Development DACH, Medicus AI. “The implementation and documentation of testing on a scale of this kind entails significant efforts and binds scarce time, human and financial resources. This is why we worked with Roche Diagnostics Germany to develop the SafePlay solution; to provide relief across all steps in the testing workflow,” he adds.

“I’m very pleased that we, in cooperation with Medicus AI, are making a significant contribution to relieving the medical staff and simplifying the workflow associated with antigen testing,” says Christian Paetzke, General Manager, Roche Diagnostics Germany. The workflow for rapid antigen testing covers many steps across all stakeholders starting from the patient registration to the actual testing all the way to the legally mandated reporting guidelines to the authorities, all of which take time and are prone to human errors, especially since medical personnel is scarce and often overworked. With SafePlay, manual work is reduced significantly which means there is less need for coordination between individuals and documentation can happen almost automatically.

“After successfully implementing the solution at our testing center in Munich, we have quickly decided to roll out the solution to all our antigen testing teams (mobile and fix centers) in Germany,” says Dr. Beatus Buchzik, Head of Solutions & Strategy, 21Dx. The company is one of Germany’s largest testing providers covering elderly homes, refugee centers, schools, corporates, and commuters at borders in addition to several testing stations across Germany.

“The feedback that companies like 21Dx provided during the development of the solution was invaluable in making Medicus SafePlay a solution that adds immediate value to anyone who wants to deploy rapid antigen testing,” adds Vartian. “The challenge now is to continuously adapt the solution to all client needs, no matter their use case.”


Related articles


Image analysis integration

Roche opens access to digital pathology tools

Roche announced the introduction of the Roche Digital Pathology Open Environment that allows software developers to easily integrate their image analysis tools for tumour tissue with Roche’s uPath…


Sponsored • Automation

Proven Practices for Lab Automation Success

Cost constraints, higher workloads, and a shortage of qualified staff are three distinct market trends driving demand for greater efficiency in the laboratory. The goals of automation are to make…


Article •

Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche

Samsung BioLogics today announced that Samsung BioLogics and F. Hoffmann-La Roche have entered into a long term strategic manufacturing agreement under which Samsung will manufacture Roche's…

Related products

Subscribe to Newsletter